Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Merger or Acquisition (March 2015)
22 slides from Teva Pharmaceutical Industries's merger presentation, Mar 30, 2015
Slide 1: Teva Announces the Acquisition of Auspex
1 Teva Announces the Acquisition of Auspex March 30, 2015
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
2 Cautionary Statement Regarding Forward-Looking 2 Statements This presentation contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or
Slide 3: Transaction Overview
3 Transaction Overview 3 Teva Announces the Acquisition of Auspex Pharmaceuticals Agreement to acquire Auspex Pharmaceuticals for $101.00 per share in cash Emerging leader in movement disorders that will expand and strengthen the leadership position of our core CNS franchise Attractive close-t
Slide 4: Strategic Rationale
4 Strategic Rationale 4 A Compelling Value-Enhancing Transaction That Fits Our Long-Term Strategy Excellent strategic fit strengthening Teva’s leadership in central nervous system disorders Builds on our infrastructure, capabilities and strong commercial and R&D position Opportunity to establish lea
Slide 5: Alignment with Teva's Business Development Strategy
5 Alignment with Teva’s Business Development Strategy 5 Auspex Brings to Teva Attractive Close-to-Market and Pipeline Assets in CNS Targeting a Unique Space In The Industry Attractive Growth Markets Pipeline Assets/ Portfolios Unique Health Solutions, Complex/Hard to Technologies, Services In-Market
Slide 6: Company Overview
6 Company Overview 6 An Innovative Leader in Movement Disorders Auspex Pharmaceuticals Background & History Innovative biopharma company specializing in applying deuterium chemistry to known molecules to create novel therapies with improved safety and efficacy profiles Founded in 2001 Headquar
Slide 7: Transaction Highlights
7 Transaction Highlights 7 Key Transaction Terms and Details Tender offer for all outstanding shares of Auspex for $101.00 per share in cash 42.4% premium to Auspex’s closing share price of $70.91 on March 27, 2015, and 37.9% premium to Deal Terms Auspex’s average closing price over last 30 days
Slide 8: Auspex: Multiple Horizons for Growth
8 Auspex: Multiple Horizons for Growth 8 Near-Term Opportunity in HD Serves as Anchor for Establishing Sustainable Leadership in Movement Disorders; Deep Pipeline Other Pipeline Idiopathic Pulmonary Patients Served Fibrosis Ph. 1 results: mid-20151 SD-809 Tourette Syndrome Parkinson’s Disease Ph. 1b
Slide 9: The Opportunity in Movement Disorders
9 The Opportunity in Movement Disorders 9 Serious Medical Conditions That Share Common Underlying Mechanism Major movement disorders: Huntington’s disease (HD) Tardive dyskinesia (TD) Tourette syndrome (TS) Common symptoms: Tics, chorea, dyskinesia, and dystonia Significant unmet medical
Slide 10: Tetrabenazine: Significant Side Effects; TID Dosing
10 Tetrabenazine: Significant Side Effects; TID Dosing 10 The Limitations of the Only Approved Drug for HD in the U.S. Frequency of Adverse Events: Tetrabenazine (%) Placebo (%) Depression 19% - Somnolence 31% 3% Akathisia 19% - Anxiety / Aggravated Anxiety 15% 3% Irritability 9% 3% Fatigue 22% 13%
Slide 11: SD-809: The Promise of Deuterated Tetrabenazine
11 SD-809: The Promise of Deuterated Tetrabenazine 11 Demonstrated, Differentiated Pharmacokinetic Profile DEUTERIUM Advantages of D Substitution: Targeted deuterium No change in shape, size, charge, or target chemical modifications pharmacology of small molecules in an approved drug Can improve
Slide 12: Deuteration Reduces the Breakdown of Active Metabolites
12 Deuteration Reduces the Breakdown of Active Metabolites 12 O-desmethyl SD-809 Active Dihydrodeutetrabenazine Deutetrabenazine Metabolites (ODM) Rapid, Extensive Deuterium Attenuates Hepatic Conversion Metabolic Breakdown of alpha and beta CYP2D6
Slide 13: In Phase 3: SD-809 Met Primary Endpoint
13 In Phase 3: SD-809 Met Primary Endpoint 13 Established Efficacy in HD Improvement in Chorea Score (TMC) Improvement in Total Motor Score (TMS) 7.4 4.4 3.4 1.9 Placebo SD-809 Placebo SD-809 Improvement in TMC Score Improvement in TMS Score from baseline to from baseline to maintenance therapy main
Slide 14: SD-809: Favorable Side Effect Profile; BID Dosing
14 SD-809: Favorable Side Effect Profile; BID Dosing 14 Frequency of Adverse Events: SD-809 Placebo (%) Depression 4% 7% Somnolence 11 % 4% Akathisia / Restlessness 2% 2% Anxiety 2% 2% Irritability 7% 13 % Fatigue 7% 4% Insomnia 7% 4% Parkinsonism / Bradykinesia 0% 0% QT Prolongation: < 5 millisecon
Slide 15: SD-809: Upcoming Milestones
15 SD-809: Upcoming Milestones 15 Mid-2015 2016 NDA HD submission Ph 2/3 results Ph 2/3 results NDA TD (ARM-TD study) (AIM-TD study) submission Phase 2/3 TS Ph1b results Initiation
Slide 16: Additional Pipeline Assets
16 Additional Pipeline Assets 16 SD-560 Indication: Idiopathic Pulmonary Fibrosis In Phase 1 results in mid-2015 SD-1077 Indication: Parkinson’s Disease Pre-clinical phase 1 POC results in 2016 ~ 60 drug candidates identified based on deuteration platform
Slide 17: Highly Complementary to Teva's Existing Specialty Pipeline
17 Highly Complementary to Teva’s Existing Specialty Pipeline 17 Phase 1 Phase 2 Phase 3 Registration TV-46763 (abuse deterrent) Laquinimod Laquinimod CEP-33237 ER Hydrocodone (abuse Pain Multiple sclerosis (progressive forms) Multiple sclerosis (relapsing remitting) det.) US - Pain TV-46139 (abuse
Slide 18: SD-809: Significant Near-Term Commercial Opportunity
18 SD-809: Significant Near-Term Commercial Opportunity 18 SD-809 Provides Substantial Addressable Market Opportunities with Significant Commercial Potential % of Physicians that Suggested Estimated Patient Population (US) Other Considerations They Would Prescribe SD-8091 Only one approved drug in
Slide 19: Teva's Existing Capabilities Aligned to Launch Auspex Assets
19 Teva’s Existing Capabilities Aligned to Launch Auspex Assets 19 Successful Launch Underpinned by Teva’s Current Presence in Sales, Marketing, Access, Medical and Patient Support Programs in the Neurology Space Recognized Market Access Track-record of commercial capabilities in US & EU Demonstrate
Slide 20: Final Remarks
20 20 Final Remarks
Slide 21: Q&A
21 21 Q&A
Slide 22: Thank You
22 Thank You
Teva Pharmaceutical Industries — Merger or Acquisition (March 2015) on 6ix